Identification of Trypanosoma cruzi Growth Inhibitors with Activity In Vivo within a Collection of Licensed Drugs

Chagas disease, caused by the parasite Trypanosoma cruzi (T. cruzi), affects more than six million people worldwide, with its greatest burden in Latin America. Available treatments present frequent toxicity and variable efficacy at the chronic phase of the infection, when the disease is usually diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Peinado, Nieves, Cortes-Serra, Nuria, Sherman, Julian, Rodriguez, Ana, Bustamante, Juan M., Gascon, Joaquim, Pinazo, Maria-Jesus, Alonso-Padilla, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920067/
https://www.ncbi.nlm.nih.gov/pubmed/33669310
http://dx.doi.org/10.3390/microorganisms9020406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920067/
https://www.ncbi.nlm.nih.gov/pubmed/33669310
http://dx.doi.org/10.3390/microorganisms9020406

Ejemplares similares